Physician profile
Jordan S Rush
NPI 1811981756
$763.38
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $33.81 · 2021: $76.89 · 2022: $353 · 2023: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $162.77 | 2019-2023 | Lo Loestrin Fe |
| Aspira Women'S Health INC | $158.63 | 2022 | |
| Therapeuticsmd, INC. | $88.78 | 2019-2022 | |
| Astellas Pharma US INC | $52.13 | 2022-2023 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $46.35 | 2019-2023 | Summit Doppler |
| Bayer Healthcare Pharmaceuticals INC. | $42.67 | 2023 | |
| Myovant Sciences INC. | $38.40 | 2022 | |
| Pfizer INC. | $32.24 | 2022 | |
| Duchesnay USA Incorporated | $24.78 | 2019 | |
| Mayne Pharma Commercial LLC | $19.92 | 2023 | |
| Agile Therapeutics, INC. | $19.77 | 2022 | |
| Exeltis, USA INC. | $18.50 | 2022 | |
| Organon LLC | $18.08 | 2022 | |
| Scynexis, INC. | $15.89 | 2022 | |
| Evofem Biosciences, INC. | $12.61 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.